Skip to main content

Table 1 Observed and expected cancer cases among digitoxin users.

From: Digitoxin medication and cancer; case control and internal dose-response studies

ICD-10 Site Sex Observed Expected SIR (95 % CI)
C50 Breast F 57 45.7 1.25(0.95, 1.62)
C61 Prostate M 108 86.7 1.25(1.03, 1.50)
C18–21 Colo-rectal M+F 127 98.5 1.29(1.06, 1.51)
C32–34 Lung M+F 63 46.4 1.35(1.04, 1.74)
C64,C65,C67,C68 Kidney, urinary M+F 59 51.8 1.14(0.87, 1.47)
C43.C44 Melanoma, other skin M+F 61 49.7 1.23(0.94, 1.58)
C81–C85,C88–C92 Leukemia/Lymphoma M+F 53 37.5 1.41 (1.06, 1.85)
C00–C97 All sites M+F 641 502.8 1.27(1.18, 1.37)
  1. Observed and expected cancer cases amoung digitoxin users, and standardized incidence ratio (SIR) presented for all types of cancers having more than 30 expected cases. The cancer types are divided in the groups according to ICD-10 (International Classification of Disease).Observed=cancer cases in the population on digitoxin after start on the drug,no lag time applied. Expected=expected cancer cases calculated by applying the national cancer rates matched exactly on year of birth,age and sex.